Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceutical Chemicals
Bachem plans third Swiss peptide and oligonucleotide plant
by Michael McCoy
October 8, 2022
| A version of this story appeared in
Volume 100, Issue 36
The Swiss firm Bachem says it will spend about $760 million to build a third peptide and oligonucleotide plant in Switzerland. The company says it expects to employ more than 500 people at the new site, in Sisslerfeld, by 2030. Bachem is in the process of spending about $560 million to expand its facility in Bubendorf, Switzerland. According to the firm, the large investments are a response to growth in peptides and oligonucleotides as active pharmaceutical ingredients.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter